CTI BioPharma Corp Revenue and Competitors
Estimated Revenue & Valuation
- CTI BioPharma Corp's estimated annual revenue is currently $43M per year.
- CTI BioPharma Corp's estimated revenue per employee is $193,750
- CTI BioPharma Corp's total funding is $185.8M.
Employee Data
- CTI BioPharma Corp has 222 Employees.
- CTI BioPharma Corp grew their employee count by -21% last year.
CTI BioPharma Corp's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP and Chief Staff | Reveal Email/Phone |
2 | EVP, CFO | Reveal Email/Phone |
3 | Sr. VP, Human Resource Development | Reveal Email/Phone |
4 | VP Market Access, Distribution & Reimbursement | Reveal Email/Phone |
5 | VP US Sales and Sales Operations | Reveal Email/Phone |
6 | Sr. VP, Biometrics | Reveal Email/Phone |
7 | SVP, Global Pharmaceutical Operations and Drug Development | Reveal Email/Phone |
8 | VP, Quality | Reveal Email/Phone |
9 | Head Portfolio Strategy and Alliance Management | Reveal Email/Phone |
10 | VP Human Resources | Reveal Email/Phone |
CTI BioPharma Corp Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4096.4M | 10837 | 2% | N/A | N/A |
What Is CTI BioPharma Corp?
CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers. We see patients as people, looking at potential therapies from the patient’s perspective to address both the clinical need and the impact treatment can have on a patient’s life. We prioritize the patient experience and are committed to developing therapeutic options for people living with cancer who want a chance at a longer and better quality of life.
keywords:N/A
$185.8M
Total Funding
222
Number of Employees
$43M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CTI BioPharma Corp News
CTI BioPharma Corp has a Long-Term Technical rank of 99. This means that trading over the last 200 trading days has placed the company in the...
CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating. Apr. 11, 2022 1:44 AM ETCTI BioPharma Corp. (CTIC)MOR, SCYX4 Comments1 Like.
SEATTLE, March 31, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and...
SEATTLE, Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to seventeen new employees as equity inducement awards outside of the Company's Amended and Re ...
SEATTLE, Aug. 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restate ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $78.9M | 222 | 0% | N/A |
#2 | $65.9M | 222 | -1% | N/A |
#3 | $65.9M | 222 | 37% | N/A |
#4 | $49.6M | 223 | N/A | N/A |
#5 | $54M | 223 | -2% | N/A |